81 results on '"MING-CHUN HSU"'
Search Results
2. Identification of Minuscule Inward Currents as Precursors to Membrane Electroporation-Induced Currents: Real-Time Prediction of Pore Appearance
- Author
-
Edmund Cheung So, Ke-Li Tsai, Fang-Tzu Wu, Ming-Chun Hsu, King-Chuen Wu, and Sheng-Nan Wu
- Subjects
Membrane electroporation ,Ion current ,Principal component analysis (PCA) ,Palmitoyl-L-carinitine ,Physiology ,QP1-981 ,Biochemistry ,QD415-436 - Abstract
Background/Aims: The objective of this study is to examine the current signals in response to large hyperpolarizations with the aid of principal component analysis (PCA) to search for or even predict current fluctuations related to membrane electroporation-induced current (IMEP). Methods: The characteristics of principal eigenvalues generated for IMEP and the current signals at 10 sec prior to the start of initial IMEP (IPre) were examined. As membrane hyperpolarizations were applied at 0.1 Hz, the appearance of IMEP coincided with the higher principal eigenvalues extracted in PCA. Results: Subsequent addition of LaCl3 (100 µM) greatly reduced IMEP and associated principal eigenvalues. In real-time analysis for a single frame (i.e, 300 msec), in response to large hyperpolarization, multiple runs of heralded minuscule inward currents (Imin) occurring before large rise in current amplitudes were detected. With PCA, such heralded Imin was noted to coincide with the extreme principal eigenvalues. The duration of Imin together with large principal eigenvalues was influenced by different levels of membrane hyperpolarization. In GH3 cells, palmitoyl-L-carnitine (PALCAR), a long-chain acylcarnitine, effectively increased the IMEP amplitude with an EC50 value of 2.4 µM. However, in PALCAR-treated cells, the Imin together with higher principal eigenvalues disappeared, while in isoflurane-treated cells, Imin occurring before large rise of current amplitude remained intact. Similarly, the PCA analysis from IPre in RAW 264.6 macrophages showed the presence of herald Imin accompanied by the extreme principal eigenvalues. Conclusion: It is clear from this study that these large principal eigenvalues are representative of MEP-associated formation of electropores. Therefore, different compositions around the surface membrane of cells may alter the appearance of Imin followed by IMEP emergence.
- Published
- 2013
- Full Text
- View/download PDF
3. Development of a Taiwanese Speech Synthesis System Using Hidden Markov Models and a Robust Tonal Phoneme Corpus.
- Author
-
Yung-Ji Sher, Ming-Chun Hsu, Yu-Hsien Chiu, Yeou-Jiunn Chen, Chung-Hsien Wu 0001, and Jiunn-Liang Wu
- Published
- 2024
4. Exponential Random Graph Modeling of Co-Offender Drug Crimes.
- Author
-
Fu-Ching Tsai, Ming-Chun Hsu, and Da-Yu Kao
- Published
- 2020
- Full Text
- View/download PDF
5. Exploring drug-related crimes with social network analysis.
- Author
-
Fu-Ching Tsai, Ming-Chun Hsu, Chien-Ta Chen, and Da-Yu Kao
- Published
- 2019
- Full Text
- View/download PDF
6. Area-Selective Growth of Two-Dimensional Mono- And Bilayer WS2 for Field Effect Transistors
- Author
-
Lin-Yun Huang, Ming-Yang Li, San-Lin Liew, Shih-Chu Lin, Ang-Sheng Chou, Ming-Chun Hsu, Ching-Hao Hsu, Yu-Tung Lin, Po-Sen Mao, Duen-Huei Hou, Wei-Cheng Liu, Chih-I Wu, Wen-Hao Chang, Han Wang, Lain-Jong Li, and Kung-Hwa Wei
- Subjects
General Chemical Engineering ,Biomedical Engineering ,General Materials Science - Published
- 2023
7. High-Performance Monolayer WSe2 p/n FETs via Antimony-Platinum Modulated Contact Technology towards 2D CMOS Electronics
- Author
-
Ang-Sheng Chou, Yu-Tung Lin, Yuxuan Cosmi Lin, Ching-Hao Hsu, Ming-Yang Li, San-Lin Liew, Sui-An Chou, Hung-Yu Chen, Hsin-Yuan Chiu, Po-Hsun Ho, Ming-Chun Hsu, Yu-Wei Hsu, Ning Yang, Wei-Yen Woon, Szuya Liao, Duen-Huei Hou, Chao-Hsin Chien, Wen-Hao Chang, Iuliana Radu, Chih-I Wu, H.-S. Philip Wong, and Han Wang
- Published
- 2022
8. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
- Author
-
Jerry Bagel, Carle Paul, Kurt Gebauer, Diamant Thaçi, Yin You, Susan Flavin, April W. Armstrong, Lyn Guenther, Andrew Blauvelt, Richard G. Langley, Kristian Reich, Bruce Randazzo, and Ming-Chun Hsu
- Subjects
Plaque psoriasis ,Moderate to severe ,medicine.medical_specialty ,business.industry ,Body Weight ,Antibodies, Monoclonal ,Dermatology ,Antibodies, Monoclonal, Humanized ,medicine.disease ,Severity of Illness Index ,Immunoglobulin A ,Treatment Outcome ,Guselkumab ,Double-Blind Method ,Psoriasis Area and Severity Index ,Psoriasis ,Internal medicine ,medicine ,Humans ,Body region ,Secukinumab ,In patient ,business ,Aged - Abstract
Purpose Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe plaque psoriasis. Materials and methods ECLIPSE, was a Phase 3, multicenter, 56-week, double-blinded, active-comparator study of guselkumab vs. secukinumab (IL-17A inhibitor) in patients with moderate-to-severe psoriasis. Patients were treated with guselkumab 100 mg (n = 534) or secukinumab 300 mg (n = 514) through week 44. Efficacy (at least a 90% and 100% improvement from baseline in Psoriasis Area and Severity Index [PASI 90 and PASI 100], Investigator's Global Assessment [IGA] 0/1, and IGA 0) was analyzed across subpopulations defined by baseline: age ( Results Overall, 1048 patients were randomized. At week 48, numerically greater proportions of patients achieved PASI 90, PASI 100, IGA 0/1, and IGA 0 with guselkumab vs. secukinumab regardless of baseline age, body weight, BMI, disease severity, body region, and prior medication. The largest differences were in patients ≥65 years old and patients weighing >100 kg. Conclusions Guselkumab treatment provided greater efficacy vs. secukinumab at week 48 in most subpopulations of patients with psoriasis.
- Published
- 2021
9. Chip Design of an UWB, High Gain and Low Noise Amplifier for Wireless Applications.
- Author
-
Jhin-Fang Huang, Ming-Chun Hsu, Jiun-Yu Wen, and Ron-Yi Liu
- Published
- 2011
- Full Text
- View/download PDF
10. Development of a Taiwanese Speech Synthesis System Using Hidden Markov Models and a Robust Tonal Phoneme Corpus
- Author
-
YUNG-JI SHER, Chung-Hsien Wu, Yu-Hsien Chiu, Yeou-Jiunn Chen, Ming-Chun Hsu, and Jiunn-Liang Wu
- Published
- 2022
11. Associations between objectively measured overall and intensity-specific physical activity and phase angle in older adults
- Author
-
Jiaren Chen, Ting-Fu Lai, Chien-Yu Lin, Ming-Chun Hsueh, Jong-Hwan Park, and Yung Liao
- Subjects
Medicine ,Science - Abstract
Abstract Phase angle (PhA) is an indicator of cellular health and is positively associated with overall physical activity (PA). However, varied associations between different intensities of PA and PhA by body segment in older populations remain unexplored. We investigated the associations between overall and different intensities of PA and upper-, lower-, and whole-body PhA in older adults. Overall exposure to light-intensity (LPA), moderate-intensity (MPA), and vigorous-intensity physical activity (VPA) was assessed using a triaxial accelerometer (GT3X + , ActiGraph). The outcome variables were upper-, lower-, and whole-body PhA measured using bioelectrical impedance analysis (MC-780MA, TANITA). Multiple linear regression helped examine the associations between the exposure and outcome variables after adjusting for age, gender, body mass index, and accelerometer wear time. A cross-sectional analysis involved 166 community-dwelling older participants (mean age = 72.1 ± 5.5 years; 78.3% women). Overall PA was associated with larger upper- (B: 0.057, 95% confidence interval [CI] 0.018–0.095) and whole-body PhA (B: 0.044, 95% CI 0.006–0.081). LPA was associated with larger upper-body PhA (B: 0.059, 95% CI 0.017–0.101), and MPA was associated with larger lower- (B: 0.273, 95% CI 0.128–0.419) and whole-body PhA (B: 0.141, 95% CI 0.002–0.280). VPA and PhA were not associated. Future interventions targeting PhA in older adults should consider the differential impact of PA intensity on various body segments of the PhA.
- Published
- 2024
- Full Text
- View/download PDF
12. Domain-specific Physical Activity and the Risk of All-cause Mortality Among Middle-aged and Older Adults in Taiwan: A Prospective Cohort Study
- Author
-
Yu-Tai Liu, Yung Liao, Ming-Chun Hsueh, Hsin-Yen Yen, Jong-Hwan Park, and Jae Hyeok Chang
- Subjects
all-cause mortality ,leisure-time physical activity ,household physical activity ,cohort study ,Medicine (General) ,R5-920 - Abstract
Background: The impact of meeting leisure-time physical activity (LTPA) recommendations and household physical activity (HPA) on all-cause mortality in the Taiwanese population is unclear. We aimed to investigate the relationship between sufficient LTPA and all-cause mortality in middle-aged and older Taiwanese adults and the role of HPA in those with insufficient LTPA. Methods: This nationwide prospective cohort study included 4,960 participants aged ≥50 years from the Taiwan Longitudinal Study in Aging (TLSA) survey. Physical activity patterns were assessed in 2003 and then followed up until 2015 for mortality through the National Death Registration Record. Cox proportional hazards regression was conducted to evaluate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Results: Of the 4,960 participants, 1,712 died of all-cause mortality. Compared to those who had insufficient LTPA, participants who engaged in sufficient LTPA showed a significantly lower risk of all-cause mortality (HR = 0.84, 95% CI, 0.73–0.97). For those with insufficient LTPA, HPA also had a significantly reduced risk of all-cause mortality (HR = 0.85, 95% CI, 0.75–0.96) among general population. Similar associations were observed in subsequent sensitivity analyses. The subgroup analysis showed that the relationship between HPA and reduced mortality risk was only found in the women with insufficient LTPA group. Conclusion: This study confirmed that sufficient LTPA is associated with a lower risk of all-cause mortality. If sufficient LTPA cannot be performed, additional HPA is related to lower mortality.
- Published
- 2023
- Full Text
- View/download PDF
13. P279 Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year
- Author
-
Chetan Karyekar, Laura C. Coates, Ming-Chun Hsu, Joseph F. Merola, Shu Li, Bruce Randazzo, Patricia C Gorecki, and Susan Flavin
- Subjects
Plaque psoriasis ,medicine.medical_specialty ,Head to head ,business.industry ,Dermatology ,Double blind ,Guselkumab ,Rheumatology ,Comparison study ,medicine ,Pharmacology (medical) ,In patient ,Secukinumab ,business ,Eclipse - Abstract
Background Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to 30% of patients with PsO may have psoriatic arthritis (PsA). The ECLIPSE study compared efficacy and safety of GUS vs SEC in patients with plaque PsO. Post hoc analyses examined outcomes in the subgroup of patients with self-reported PsA. Methods ECLIPSE was a randomised, double-blind trial of adults with moderate-to-severe plaque PsO who received GUS 100 mg at Week (W)0, W4, then every 8 weeks, or SEC 300 mg at W0, W1, W2, W3, and W4, then every 4 weeks, both through W44. The primary endpoint was the proportion of patients achieving ≥90% improvement compared to baseline in the Psoriasis Area and Severity Index (PASI) score at W48. Cochran-Mantel Haenszel chi-square testing stratified by investigator was used to compare treatment-group responses. Results Overall, treatment groups [GUS (n = 534), SEC (n = 514)] were comparable at baseline: weight 89 kg, 24% body surface area PsO, and Investigator Global Assessment (IGA) moderate (76%) or severe (24%). These characteristics were similar to those of subgroups with self-reported PsA [GUS (n = 97), SEC (n = 79)]. In the overall population, the primary endpoint of PASI 90 response at W48 was achieved by 84.5% of GUS vs 70.0% of SEC patients (treatment difference 14.2 [95% CI = 9.6%, 18.8%], P < 0.001). Among patients with PsA, the primary endpoint of PASI 90 response at W48 was achieved by 82.5% of GUS vs 63.3% of SEC patients (treatment difference 19.2% [95% CI = 5.0%, 33.4%]). Beyond Week 20, in both the overall study population and the PsA subpopulation, GUS-treated patients maintained the PASI 90 response while SEC-treated patients had a reduction in response through W48. In the overall population, results of the first major secondary endpoint (proportion of patients with a PASI 75 response at both W12 and W48) showed non-inferiority of GUS vs SEC (GUS-84.6% vs SEC-80.2% of patients, p < 0.001), but superiority was not demonstrated (p = 0.062). Adverse events (AEs) observed in the overall population and PsA subgroup were generally consistent with the established safety profiles for GUS and SEC. Conclusion In the subset of patients with self-reported PsA in the ECLIPSE study, GUS demonstrated better maintenance of response and higher efficacy at approximately one year compared with SEC in the treatment of moderate to severe plaque PsO. These findings were consistent with those for the overall study population of patients with plaque PsO. AEs observed were generally consistent with the established safety profiles for GUS and SEC. Disclosures J.F. Merola: Other; J.M. has been a study investigator for Janssen. S. Li: Other; S.L. is a Janssen employee. M. Hsu: Other; M.H. is a Janssen employee. C. Karyekar: Other; C.K. is a Janssen employee. P.C. Gorecki: Other; P.G. is a Janssen employee. S. Flavin: Other; S.F. is a Janssen employee. B. Randazzo: Other; B.R. is a Janssen employee. L.C. Coates: Other; L.C. has been a study investigator for Janssen.
- Published
- 2020
14. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study
- Author
-
K. Barber, Shu Li, Yaowei Zhu, Ming-Chun Hsu, Alan Menter, Lawrence F. Eichenfield, Amy S. Paller, Arjen Nikkels, Sandra Philipp, S. DePrimo, Ian Landells, Michael Song, and Bruce Randazzo
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Dermatology ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Psoriasis Area and Severity Index ,Psoriasis ,Internal medicine ,Ustekinumab ,medicine ,Clinical endpoint ,Humans ,Adverse effect ,Child ,business.industry ,Incidence (epidemiology) ,Antibodies, Monoclonal ,Dermatology Life Quality Index ,medicine.disease ,Treatment Outcome ,Interleukin 17 ,business ,Biomarkers ,medicine.drug - Abstract
BACKGROUND Limited options are available for treatment of paediatric psoriasis. OBJECTIVES To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (≥ 6 to 100 kg: 90 mg) administered by subcutaneous injection at weeks 0 and 4, then every 12 weeks through week 40. Study endpoints (all at week 12) included the proportions of patients achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) and ≥ 75%/90% improvement in Psoriasis Area and Severity Index (PASI 75/90), and change in Children's Dermatology Life Quality Index (CDLQI). Serum ustekinumab concentrations, antidrug antibodies and cytokine levels were measured through week 52. Safety was evaluated through week 56. RESULTS In total, 44 patients (median age 9·5 years) received at least one dose of ustekinumab. Three patients discontinued the study agent through week 40. At week 12, 77% of patients achieved PGA 0/1, 84% achieved PASI 75 and 64% achieved PASI 90 response. The mean change in CDLQI was -6·3. Trough serum ustekinumab concentrations reached steady state at weeks 28-52. The incidence of antidrug antibodies was 10% (n = 4). Mean serum concentrations of interleukin-17A/F and interleukin-22 were significantly reduced at weeks 12 and 52. Overall, 34 patients (77%) had at least one adverse event and three (7%) had a serious adverse event. CONCLUSIONS Ustekinumab effectively treated moderate-to-severe psoriasis in paediatric patients, and no new safety concerns were identified. What is already known about this topic? Ustekinumab is approved for use in adolescents (≥ 12 to < 18 years of age) and adults (≥ 18 years) with moderate-to-severe psoriasis. What does this study add? Ustekinumab effectively treats moderate-to-severe psoriasis in paediatric patients (≥ 6 to < 12 years of age), with no new safety concerns. Linked Comment: Reich. Br J Dermatol 2020; 183:606-607.
- Published
- 2020
15. Exponential Random Graph Modeling of Co-Offender Drug Crimes
- Author
-
Ming-Chun Hsu, Fu-Ching Tsai, and Da-Yu Kao
- Subjects
Social network ,Recidivism ,business.industry ,Computer science ,Social network analysis (criminology) ,020206 networking & telecommunications ,Markov chain Monte Carlo ,02 engineering and technology ,medicine.disease ,Homophily ,Substance abuse ,Social security ,symbols.namesake ,Crime prevention ,Intervention (counseling) ,Exponential random graph models ,0202 electrical engineering, electronic engineering, information engineering ,Econometrics ,symbols ,medicine ,020201 artificial intelligence & image processing ,business - Abstract
Drug problem has contributed a rapid impact on today's society. It is not only a threat of human health but also causes a great impact on the social security issue. As drug abuse tends to organized crimes, we must consider the social network relationships among criminals to formulate better strategies against drugs. This research applied exponential random graph models (ERGMs) to analyze dynamic relations of drug crime. The strength of ERGMs is the ability to handle complicated dependency patterns which violate the basic assumption of traditional statistical methodologies. The homophily test and Monte Carlo Markov Chain (MCMC) estimation are used to explore the drug offenders' attributes and structural interactions, respectively. The experimental result shows that the homophily effect is significant on drug co-offenders relations regarding to occupation, education, nationality, drug type and recidivism. In addition, the positive 2-path coefficient indicates that drug offenders tend to share friends and form a cluster. The results of this paper reveal the advantages of structural implications in analyzing drug-related crime, as well as its ability to facilitate the cognition of crime prevention and intervention strategies.
- Published
- 2020
16. Objective assessment of the association between frailty and sedentary behavior in older adults: a cross-sectional study
- Author
-
Wen-Ning Chang, Pei-Lin Tzeng, Wei-Jia Huang, Yu-Hung Lin, Kun-Pei Lin, Chiung-Jung Wen, Yi-Chun Chou, Yung Liao, Ming-Chun Hsueh, and Ding-Cheng Chan
- Subjects
Older adults ,Frailty ,Sedentary behavior ,Accelerometer ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Given the inconsistent findings of the association between frailty and sedentary behavior in older adults, this cross-sectional study investigated the aforementioned association using four different frailty criteria and two sedentary behavior indices in older adults. Methods Data from older adults (age ≥ 65 y) who participated in health examinations or attended outpatient integrated clinics at a medical center in Taipei, Taiwan, were collected. Frailty was measured using the modified Fried Frailty Phenotype (mFFP), Clinical Frailty Scale in Chinese Translation (CFS-C), Study of Osteoporotic Fractures (SOF) index, and Clinical Frailty-Deficit Count (CF-DC) index; sedentary behavior was assessed with a waist-worn accelerometer. Adjusted linear regression ascertained the association between frailty and both sedentary behavior outcomes. Results Among the 214 participants (mean age 80.82 ± 7.14 y), 116 were women. The average total sedentary time and number of sedentary bouts were 609.74 ± 79.29 min and 5.51 ± 2.09 times per day, respectively. Frail participants had a longer total sedentary time (odds ratio [OR]: 30.13, P = .01 and 39.43, P
- Published
- 2023
- Full Text
- View/download PDF
17. Newton Output Blocking Force under Low-Voltage Stimulation for Carbon Nanotube–Electroactive Polymer Composite Artificial Muscles
- Author
-
Dai-Xuan Zhong, Ming-Chia Yang, Yi-Wen Chen, Chia-Hui Yang, Ming-Chun Hsu, and I-Wen Peter Chen
- Subjects
Materials science ,Polymers ,Composite number ,Ionic bonding ,02 engineering and technology ,Carbon nanotube ,010402 general chemistry ,01 natural sciences ,law.invention ,Biomimetics ,law ,Electroactive polymers ,General Materials Science ,Composite material ,Ions ,chemistry.chemical_classification ,Nanotubes, Carbon ,Polymer ,Condensed Matter::Mesoscopic Systems and Quantum Hall Effect ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,chemistry ,Artificial muscle ,0210 nano-technology ,Low voltage ,Voltage - Abstract
This is a study on the development of carbon nanotube-based composite actuators using a new ionic liquid-doped electroactive ionic polymer. For scalable production purposes, a simple hot-pressing method was used. Carbon nanotube/ionic liquid-Nafion/carbon nanotube composite films were fabricated that exhibited a large output blocking force and a stable cycling life with low alternating voltage stimuli in air. Of particular interest and importance, a blocking force of 1.5 N was achieved at an applied voltage of 6 V. Operational durability was confirmed by testing in air for over 30 000 cycles (or 43 h). The superior actuation performance of the carbon nanotube/ionic liquid-Nafion/carbon nanotube composite, coupled with easy manufacturability, low driving voltage, and reliable operation, promises great potential for artificial muscle and biomimetic applications.
- Published
- 2017
18. Amélioration du score PASI absolu chez des patients atteints de psoriasis traités par le guselkumab ou le sécukinumab: résultats de l’étude ECLIPSE
- Author
-
M.P. Konstantinou, Andrew Blauvelt, Kristian Reich, C. Maari, Susan Flavin, J. Soung, Bruce Randazzo, Diamant Thaçi, K. Gebauer, and Ming-Chun Hsu
- Subjects
Dermatology - Abstract
Introduction ECLIPSE est une etude de phase 3, randomisee, en double aveugle, multicentrique, controlee vs comparateur actif, visant a comparer l’efficacite et la tolerance du guselkumab (GUS) et du secukinumab (SEC) chez des patients atteints de psoriasis en plaques modere a severe. Le GUS a demontre une superiorite par rapport au SEC sur le critere principal d’evaluation: le PASI 90 a la semaine 48. L’objectif de cette analyse a ete d’evaluer la reponse au travers des scores de PASI absolu obtenus a la semaine 48 sous GUS et SEC dans cette etude. Materiel et methodes Les patients ont ete randomises pour recevoir 100 mg de GUS par injection sous-cutanee (SC) aux semaines 0, 4, 12, puis toutes les 8 semaines (n = 534) ou 300 mg de SEC par SC aux semaines 0, 1, 2, 3, 4, puis toutes les 4 semaines (n = 514), avec une derniere injection de GUS comme de SEC a la semaine 44. Les resultats d’efficacite obtenus a la semaine 48, fondes sur des seuils de PASI absolus de 0, ≤ 1 et ≤ 3, sont issus d’une analyse post hoc. Les donnees manquantes ont ete imputees comme « non-repondeur ». Resultats Les donnees demographiques et les caracteristiques de la maladie a l’inclusion etaient semblables d’un groupe de traitement a l’autre. Tel que rapporte precedemment, une proportion significativement plus elevee de patients du groupe GUS a atteint le critere d’evaluation principal de la reponse PASI 90 a la semaine 48 par rapport au groupe SEC (84,5 % vs 70,0 %, respectivement; p Conclusion Le traitement par GUS a permis d’obtenir des taux de reponse numeriquement plus eleves a la semaine 48 en terme de seuils de PASI absolus par rapport au SEC.
- Published
- 2019
19. Constance de la réponse selon les quartiles de poids et les catégories de masse corporelle : résultats de l’étude ECLIPSE à la semaine 48
- Author
-
Andrew Blauvelt, Susan Flavin, M.P. Konstantinou, April W. Armstrong, Richard G. Langley, Kristian Reich, Bruce Randazzo, and Ming-Chun Hsu
- Subjects
Dermatology - Abstract
Introduction Le psoriasis est une maladie chronique necessitant un traitement a long terme. ECLIPSE est une etude de phase 3, randomisee, controlee, comparant l’efficacite du guselkumab (GUS) au secukinumab (SEC) sur 48 semaines pour le traitement du psoriasis en plaques modere a severe. Le GUS a demontre une superiorite par rapport au SEC pour le critere d’evaluation principal (proportion de patients repondeurs PASI 90 a la semaine 48 [S48]). Cette analyse a evalue l’efficacite en fonction des quartiles de masse corporelle (MC) et des categories d’indice de masse corporelle (IMC) a l’inclusion. Materiel et methodes Les patients ont ete randomises pour recevoir GUS 100 mg aux semaines 0, 4 et 12, puis toutes les 8 semaines (n = 534), ou SEC 300 mg aux semaines 0, 1, 2, 3 et 4, puis toutes les 4 semaines (n = 514), jusqu’a la semaine 44. Il n’y avait aucune restriction de poids pour participer a l’etude. Les criteres d’evaluation comprenaient les proportions de patients repondeurs PASI 90 et PASI 100 et de patients atteignant un score IGA 0 et IGA 0/1 a S48. Les donnees ont ete analysees par quartile de MC (Q1, ≤ 74 kg ; Q2, > 74 a ≤ 87 kg ; Q3, > 87 a ≤ 100 kg ; Q4, > 100 kg) et par categorie d’IMC (normal, Resultats Des proportions numeriquement plus elevees de patients ont obtenu des reponses PASI 90, PASI 100, IGA 0 et IGA 0/1 a S48 avec le GUS comparativement au SEC, dans tous les quartiles de MC ( Tableau 1 ). Les proportions de patients ayant atteint les principaux criteres d’efficacite a S48 dans les groupes GUS et SEC, respectivement (difference entre traitement[IC95 %]) par categorie d’IMC a l’inclusion etaient comme suit : PASI 90 : normal, 88,1 % vs 75,2 % (12,8 %[2,2 %, 23,5 %]) ; surpoids, 84,1 % vs 73,4 % (10,6 %[1,6 %, 19,7 %]) ; obeses, 82,5 % vs 65,3 % (17,2 %[8,8 %, 25,6 %]) ; PASI 100 : normal, 64,2 % vs 57,8 % (6,4 %[−6,8 %, 19,5 %]) ; surpoids, 61,4 % vs 53,7 % (7,7 %[−3,2 %, 18,5 %]) ; obeses, 52,5 % vs 40,4 % (12 %[2,4 %, 21,6 %]) ; IGA 0 : normal, 68,7 % vs 60,6 % (8,1 %[−4,8 %, 21,0 %]) ; surpoids, 64,2 % vs 54,2 % (10 %[−0,8 %, 20,7 %]) ; obeses, 57 % vs 43,1 % (13,8 %[4,2 %, 23,5 %]) ; IGA 0/1 : normal, 85,8 % vs 77,1 % (8,8 %[−1,9 %, 19,4 %]) ; surpoids, 86,9 % vs 81,9 % (5,0 %[−3,1 %, 13,1 %]) ; obeses, 83,0 % vs 63,9 % (13,6 %[5,4 %, 21,9 %]). Conclusion Dans les quartiles de MC et les categories d’IMC a l’inclusion, les taux de reponse a S48 etaient systematiquement plus eleves pour le GUS que pour le SEC, quels que soient les criteres, dans le traitement du psoriasis modere a severe.
- Published
- 2019
20. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- Author
-
Patrick Branigan, Richard G. Langley, Shu Li, Andrew Blauvelt, Kristian Reich, Susan Flavin, April W. Armstrong, Ming-Chun Hsu, and Bruce Randazzo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Double-Blind Method ,law ,Psoriasis Area and Severity Index ,Internal medicine ,Psoriasis ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,education ,education.field_of_study ,Biological Products ,business.industry ,Interleukin-17 ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,Clinical trial ,Guselkumab ,Treatment Outcome ,Interleukin-23 Subunit p19 ,Secukinumab ,Female ,business - Abstract
Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab.In this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either guselkumab (100 mg at weeks 0 and 4 then every 8 weeks) or secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, and then every 4 weeks). The primary endpoint, the proportion of patients in the intention-to-treat population who achieved 90% reduction or more from baseline of Psoriasis Area and Severity Index (PASI 90 response) at week 48, and major secondary endpoints (the proportions of patients in the guselkumab group and in the secukinumab group who achieved a PASI 75 response at both weeks 12 and 48, a PASI 90 response at week 12, a PASI 75 response at week 12, a PASI 100 response at week 48, an Investigator's Global Assessment [IGA] score of 0 [cleared] at week 48, and an IGA score of 0 or 1 [minimal] at week 48) were to be tested in a fixed sequence to control type I error rate. Safety was evaluated in patients who received one or more doses of study drug from week 0 to 56. The study is registered with ClinicalTrials.gov, NCT03090100.This study was done between April 27, 2017, and Sept 20, 2018. 1048 eligible patients were enrolled and, of these, 534 were assigned to receive guselkumab and 514 to receive secukinumab. The proportion of patients with a PASI 90 response at week 48 was greater in the guselkumab group (451 [84%]) than in the secukinumab group (360 [70%]; p0·0001). Although non-inferiority (margin of 10 percentage points) was established for the first major secondary endpoint (452 [85%] of patients in the guselkumab group vs 412 [80%] of patients in the secukinumab group achieving a PASI 75 response at both weeks 12 and 48), superiority was not established (p=0·0616). Consequently, formal statistical testing was not done for subsequent major secondary endpoints. Proportions of patients with adverse events, infections, and serious adverse events were similar between the two treatments and, in general, safety findings were consistent with registrational trial observations.Guselkumab showed superior long-term efficacy based on PASI 90 at week 48 when compared with secukinumab for treating moderate-to-severe psoriasis. This finding could assist health-care providers in their decision making process when selecting a biologic for treating moderate-to-severe psoriasis.This study was funded by Janssen ResearchDevelopment.
- Published
- 2019
21. SAT0390 GUSELKUMAB WAS MORE EFFECTIVE THAN SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS AND THE SUBSET OF PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS IN THE RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD COMPARISON STUDY ECLIPSE OVER 1 YEAR
- Author
-
Laura C. Coates, Ming-Chun Hsu, Li Shu, Chetan S Karyekar, Susan Flavin, Joseph F. Merola, and Bruce Randazzo
- Subjects
Body surface area ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,medicine.disease ,Psoriatic arthritis ,Guselkumab ,Psoriasis Area and Severity Index ,Psoriasis ,Internal medicine ,medicine ,Clinical endpoint ,Secukinumab ,business ,education - Abstract
Background Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to 30% of patients with PsO may have psoriatic arthritis (PsA). Objectives The ECLIPSE study compared efficacy and safety of GUS vs SEC in patients with plaque PsO. Post hoc analyses examined outcomes in the subgroup of patients with self-reported psoriatic arthritis (PsA). Methods ECLIPSE was a randomized, double-blind trial of adults with moderate-to-severe plaque PsO who received GUS 100 mg at Weeks 0, 4, then every 8 weeks, or SEC 300 mg at Weeks 0, 1, 2, 3, and 4, then every 4 weeks, both through Week 44. The primary endpoint was the proportion of patients achieving ≥90% improvement compared to baseline in the Psoriasis Area and Severity Index (PASI) score at Week 48. Cochran-Mantel Haenszel chi-square testing stratified by investigator was used to compare treatment-group responses. Results Overall, treatment groups [GUS (n=534), SEC (n=514)] were comparable at baseline: weight 89kg, 24% body surface area PsO, and Investigator Global Assessment (IGA) moderate (76%) or severe (24%). These characteristics were similar to those of subgroups with self-reported PsA [GUS (n=97), SEC (n=79)]. In the overall population, the primary endpoint of PASI 90 response at Week 48 was achieved by 84.5% of GUS vs 70.0% of SEC patients (treatment difference 14.2 [95% CI=9.6%,18.8%], P Conclusion In the subset of patients with self-reported PsA in the ECLIPSE study, GUS demonstrated better maintenance of response and higher efficacy at approximately one year compared with SEC in the treatment of moderate to severe plaque PsO. These findings were consistent with those for the overall study population of patients with plaque PsO. AEs observed were generally consistent with the established safety profiles for GUS and SEC. Disclosure of Interests Joseph F Merola Grant/research support from: Janssen, Shu Li Employee of: Janssen Research & Development, LLC, Ming-Chun Hsu Employee of: Janssen Research & Development, LLC, Chetan Karyekar Shareholder of: J&J, Employee of: Janssen Scientific Affairs, LLC, Abbott, BMS, Novartis, Susan Flavin Employee of: Janssen Research & Development, LLC, Bruce Randazzo Employee of: Janssen Research & Development, LLC, Laura C Coates Grant/research support from: AbbVie, Celgene, Lilly, Novartis and Pfizer, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead Sciences Inc., Janssen, Lilly, Novartis, Pfizer, Prothena Corp and UCB
- Published
- 2019
22. The Risk of Mortality among Psoriatic Patients with Varying Severity: A Nationwide Population-Based Cohort Study in Taiwan
- Author
-
Yun Ting Chang, Chen Yi Wu, Tzeng Ji Chen, Ming Chun Hsu, Hsiao Yun Hu, Ying Xiu Dai, and Chung Pin Li
- Subjects
Adult ,Male ,National Health Insurance Research Database ,medicine.medical_specialty ,Health, Toxicology and Mutagenesis ,Population ,Taiwan ,Arthritis ,lcsh:Medicine ,Risk Assessment ,Severity of Illness Index ,Article ,Cohort Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Psoriasis ,Risk of mortality ,Medicine ,Humans ,030212 general & internal medicine ,education ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,psoriatic arthritis ,education.field_of_study ,business.industry ,Proportional hazards model ,Incidence ,Hazard ratio ,Arthritis, Psoriatic ,lcsh:R ,Public Health, Environmental and Occupational Health ,psoriasis ,Middle Aged ,medicine.disease ,mortality ,Female ,business ,Cohort study - Abstract
Background: Previous studies showed conflicting results regarding the mortality risk in psoriasis patients with respect to disease severity and presence of psoriatic arthritis. This study aimed to determine the mortality risk in patients with mild and severe psoriasis and patients with psoriatic arthritis (PsA). Methods: A nationwide population-based cohort study was conducted based on data from the Taiwan National Health Insurance Research Database between 2002 and 2012. Incident psoriasis subjects were classified into two groups: psoriasis without arthritis and psoriasis with arthritis. Patients who had received systemic therapy and/or phototherapy were classified as having severe psoriasis, otherwise, patients were classified as having mild psoriasis. Control subjects without psoriasis were selected to match each psoriasis patient from the database within the same observational period. Cox proportional hazards analysis was used to compare the hazard ratio (HR) of time to death. Results: A total of 106,701 patients with psoriasis were included in this study. After controlling for demographics and comorbidities, psoriasis patients had a higher mortality risk compared with the control group (HR 1.41, 95% confidence interval (CI) 1.36 to 1.46). Compared with psoriasis alone, the mortality risk was not increased for PsA (HR = 1.01, 95% CI 0.93 to 1.10). Besides, severe psoriasis did not increase mortality risk compared with mild psoriasis (HR = 1.0, 95% CI 0.95 to 1.06). Conclusions: Patients with psoriasis had a higher mortality risk compared with control subjects, whereas psoriasis severity and presence of PsA had no impact on mortality risk in psoriasis patients.
- Published
- 2018
- Full Text
- View/download PDF
23. 15188 Clinical responses by self-reported PsA status at baseline among patients with moderate to severe psoriasis treated with guselkumab versus secukinumab: Week 48 results from the ECLIPSE study
- Author
-
Susan Flavin, Ronald Vender, Lyn Guenther, Alice B. Gottlieb, Yin You, Peter Foley, Kristian Reich, Ming-Chun Hsu, Bruce Randazzo, and Andrew Blauvelt
- Subjects
medicine.medical_specialty ,Guselkumab ,business.industry ,Internal medicine ,Moderate to severe psoriasis ,medicine ,Secukinumab ,Dermatology ,business ,Baseline (configuration management) ,Eclipse - Published
- 2020
24. 15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study
- Author
-
April W. Armstrong, Melinda Gooderham, Bruce Randazzo, Shu Li, Richard G. Langley, Petr Arenberger, Kurt Gebauer Probity, Susan Flavin, and Ming-Chun Hsu
- Subjects
medicine.medical_specialty ,Guselkumab ,business.industry ,Psoriasis Area and Severity Index ,Component (UML) ,medicine ,In patient ,Secukinumab ,Dermatology ,business ,Eclipse - Published
- 2020
25. Constance de la réponse selon l’âge chez des patients atteints de psoriasis modéré à sévère traités par guselkumab vs sécukinumab : résultats de l’étude ECLIPSE à la 48e semaine
- Author
-
Ming-Chun Hsu, Kim A. Papp, Kristian Reich, M.P. Kontantinou, Yves Poulin, Susan Flavin, Jerry Bagel, W. Owczarek, April W. Armstrong, Bruce Randazzo, and Peter Foley
- Subjects
Dermatology - Abstract
Introduction ECLIPSE est une etude de phase 3, multicentrique, en double aveugle, controlee vs comparateur actif, comparant le guselkumab, un anticorps monoclonal anti-IL23, et le secukinumab, un anticorps monoclonal anti-IL17A, dans le traitement a long terme de patients adultes atteints de psoriasis en plaques modere a severe. Cette analyse a evalue la constance de la reponse sous guselkumab par rapport au secukinumab dans des sous-groupes de patients predefinis en fonction de l’âge a l’inclusion. Materiel et methodes Les patients adultes (≥ 18 ans) ont ete randomises pour recevoir 100 mg de guselkumab aux semaines 0, 4 et 12, puis toutes les 8 semaines (n = 534), ou 300 mg de secukinumab aux semaines 0, 1, 2, 3, 4, puis toutes les 4 semaines (n = 514) ; jusqu’a la semaine 44. Les patients randomises pour le guselkumab ont egalement recu des injections de placebo afin de faire correspondre le nombre et la frequence des injections a celles du secukinumab afin de maintenir l’aveugle. Les proportions de patients obtenant a la semaine 48 une reponse PASI 90, une reponse PASI 100 et un score IGA 0 ont ete analysees par categorie d’âge a l’inclusion : Resultats Les proportions de patients dans chaque categorie d’âge au debut de l’etude etaient globalement comparables entre les groupes guselkumab (n = 534) et secukinumab (n = 514) : Tableau 1 ). Les taux de reponse PASI 100 et le score IGA de 0 etaient aussi numeriquement plus eleves pour le guselkumab que pour le secukinumab, pour toutes les categories d’âge ( Tableau 1 ). Conclusion A la semaine 48, le groupe guselkumab a obtenu des taux de reponse numeriquement plus eleves que le secukinumab dans le traitement du psoriasis modere a severe quelles que soient les categories de patients definies par l’âge.
- Published
- 2019
26. Constance de la réponse selon les caractéristiques de sévérité de la maladie chez les patients atteints de psoriasis modéré à sévère traités par le guselkumab par rapport au sécukinumab : résultats de l’étude ECLIPSE à la semaine 48
- Author
-
April W. Armstrong, Susan Flavin, C.H. Hong, A. Martorell, J. Weisman, Bruce Randazzo, Richard G. Langley, M.P. Konstantinou, Ming-Chun Hsu, and Pablo Fernandez-Penas
- Subjects
Dermatology - Abstract
Introduction ECLIPSE est une etude de phase 3, multicentrique, en double aveugle, controlee vs comparateur actif, comparant le guselkumab, un anticorps monoclonal anti-IL23, et le secukinumab, un anticorps monoclonal anti-IL17, dans le traitement a long terme de patients adultes atteints de psoriasis en plaques modere a severe. Cette analyse a evalue la constance de la reponse sous guselkumab par rapport au secukinumab dans des sous-groupes de patients predefinis en fonction de la severite du psoriasis a l’inclusion. Materiel et methodes Les patients ont ete randomises pour recevoir 100 mg de guselkumab aux semaines 0, 4 et 12, puis toutes les 8 semaines (n = 534), ou 300 mg de secukinumab aux semaines 0, 1, 2, 3, 4, puis toutes les 4 semaines (n = 514), jusqu’a la semaine 44. Les patients randomises pour le guselkumab ont egalement recu des injections de placebo afin de faire correspondre le nombre et la frequence des injections a celles du secukinumab afin de maintenir l’aveugle. Les proportions de patients obtenant a la semaine 48 une reponse PASI 90, une reponse PASI 100 et un score IGA de 0 ont ete analysees par categories de criteres de severite de la maladie a l’inclusion : surface corporelle atteinte (SCA) Resultats Les caracteristiques de severite de la maladie a l’inclusion etaient comparables entre les groupes guselkumab (n = 534) et secukinumab (n = 514), respectivement : SCA 20 % (53,4 % vs 53,3 %), duree de la maladie 15 ans (58,4 % vs 53,5 %), score PASI 20 (35,6 % vs 36,6 %), et score IGA de 4 (23,8 % vs 23,7 %). Comme precedemment rapporte, dans l’ensemble de la population, une proportion significativement plus elevee de patients du groupe guselkumab ont obtenu une reponse PASI 90 a la semaine 48 par rapport au groupe secukinumab (84,5 % vs 70,0 %, p Conclusion A la semaine 48, le guselkumab presentait des taux de reponse numeriquement plus eleves que le secukinumab, quelles que soient les caracteristiques de severite du psoriasis a l’inclusion.
- Published
- 2019
27. Diurnal pattern of breaks in sedentary time and the physical function of older adults
- Author
-
Ting-Fu Lai, Yung Liao, Chien-Yu Lin, Ming-Chun Hsueh, Mohammad Javad Koohsari, Ai Shibata, Koichiro Oka, and Ding-Cheng Chan
- Subjects
Aging ,Interrupting prolonged sitting ,Circadian clock ,Elderly ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background The association of breaks in sedentary time with outcomes of physical function can vary according to the time of day. We examined the association of the diurnal pattern of breaks in sedentary time with physical function outcomes in older adults. Methods A cross-sectional analysis was conducted among 115 older adults (≥60 years). The overall and time-specific breaks (morning: 06:00–12:00; afternoon: 12:00–18:00; evening: 18:00–24:00) in sedentary time were assessed using a triaxial accelerometer (Actigraph GT3X+). A break in sedentary time was defined as at least 1 min where the accelerometer registered ≥100 cpm following a sedentary period. Five physical function outcomes were assessed: handgrip strength (dynamometer), balance ability (single leg stance), gait speed (11-m walking), basic functional mobility (time up and go), and lower-limb strength (five times sit-to-stand). Generalized linear models were used to examine the associations of the overall and time-specific breaks in sedentary time with the physical function outcomes. Results Participants showed an average of 69.4 breaks in sedentary time during the day. Less frequent breaks in the evening (19.3) were found than that in the morning (24.3) and the afternoon (25.3) (p
- Published
- 2023
- Full Text
- View/download PDF
28. Effect of isotemporal substitution of sedentary behavior with different intensities of physical activity on the muscle function of older adults in the context of a medical center
- Author
-
Ting-Fu Lai, Yung Liao, Ming-Chun Hsueh, Kun-Pei Lin, Ding-Cheng Chan, Yung-Ming Chen, and Chiung-Jung Wen
- Subjects
Isotemporal substitution ,Older adults ,Muscle function ,Different proportions of physical activity ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Engaging in physical activity and reducing sedentary time in daily life may enable older individuals to maintain muscle mass. This study aimed to investigate the effects of replacing sedentary behavior with light physical activity (LPA) or moderate-to-vigorous physical activity (MVPA) on the muscle function of older adults at a medical center in Taiwan. Methods We recruited 141 older adults (51.1% men; 81.1 ± 6.9 years old) and asked them to wear a triaxial accelerometer on the waist to measure their sedentary behavior and physical activity. Functional performance was assessed based on handgrip strength, Timed Up and Go (TUG) test, gait speed, and five-times-sit-to-stand test (5XSST). Isotemporal substitution analysis was performed to examine the effect of substituting 60 min of sedentary time with 60 min of LPA, MVPA, and combined LPA and MVPA in different proportions. Results Reallocating 60 min of sedentary behavior per day to LPA was associated with better handgrip strength (Beta [B] = 1.587, 95% confidence interval [CI] = 0.706, 2.468), TUG test findings (B = -1.415, 95% CI = -2.186, -0.643), and gait speed (B = 0.042, 95% CI = 0.007, 0.078). Reallocating 60 min of sedentary behavior per day to MVPA was associated with better gait speed (B = 0.105, 95% CI = 0.018, 0.193) and 5XSST findings (B = -0.060, 95% CI = -0.117, -0.003). In addition, each 5-min increment in MVPA in the total physical activity replacing 60 min of sedentary behavior per day resulted in greater gait speed. Replacing 60 min of sedentary behavior with 30-min of LPA and 30-min of MVPA per day significantly decreased the 5XSST test time. Conclusion Our study indicates that introducing LPA and a combination of LPA and MVPA to specifically replace sedentary behavior may help maintain muscle function in older adults.
- Published
- 2023
- Full Text
- View/download PDF
29. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)
- Author
-
Abrar A. Qureshi, Kevin D. Smith, Ernesto J. Muñoz-Elías, Kavitha Goyal, K. Callis Duffin, Andrew Blauvelt, Shu Li, Ming-Chun Hsu, Steven Fakharzadeh, Craig L. Leonardi, Paul S. Yamauchi, Yanqing Chen, Laura K. Ferris, Kamyar Farahi, and Marc Chevrier
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Dermatology ,Drug Administration Schedule ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Double-Blind Method ,Psoriasis Area and Severity Index ,Internal medicine ,Psoriasis ,Ustekinumab ,Clinical endpoint ,medicine ,Humans ,Dosing interval ,Dosing ,Young adult ,Aged ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Discontinuation ,Surgery ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Dermatologic Agents ,business ,medicine.drug - Abstract
Background Phase 3 studies showed some patients maintained response for ≥6 months post-ustekinumab discontinuation. Objectives To assess clinical responses with extended ustekinumab maintenance dosing intervals. Methods Adults with moderate-to-severe plaque psoriasis received ustekinumab (45mg/90mg for weight ≤100 kg/>100 kg) at Week0, Week4, Week16 during open-label treatment. Patients achieving a Week 28 Physician's Global Assessment score of cleared/minimal (PGA=0/1) were randomized 1:4 to Group1 (approved every-12-weeks [q12wk] maintenance) or Group2 (q12-24wk response-based dosing determined by time–to-loss-of-PGA=0/1). Key endpoints included number of visits with PGA=0/1 (primary endpoint) and ≥75% improvement in Psoriasis Area and Severity Index (PASI75) between Weeks88-112, and PGA/PASI responses between Weeks28-112. Results 378 patients achieved PGA=0/1 at Week28 and were randomized to Group1 (n=76) or Group2 (n=302). Group1 patients had numerically greater mean numbers of visits with PGA=0/1 than Group2 (4.5 and 4.1, respectively; mean-difference [95%CI]: -0.46 [-1.20; 0.29]) and PASI75 (5.8 and 5.4, respectively; -0.32 [-0.96;0.33]) from Week88-112. A higher proportion of patients in Group1 (55.3%) than Group2 (38.7%) had PGA=0/1 at all seven Week88-112 visits. Maintenance of response was observed with dose-interval extension beyond q12wk (q16wk, q20wk, q24wk) in a subset of patients (28% of patients randomized to Group 2 extended maintenance dosing to q24wks and maintained high levels of response). Extending dosing interval did not affect antibody development or safety. Conclusions Efficacy was better maintained among Week28 PGA-responders randomized to continue q12wk ustekinumab versus extending maintenance dosing based on clinical response, although some patients maintained high levels of efficacy with up to q24wk dosing. This article is protected by copyright. All rights reserved.
- Published
- 2017
30. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis
- Author
-
Kristian Reich, Nehal N. Mehta, Richard G. Langley, Daniel J. Rader, Philippe Szapary, Ulrich Mrowietz, Newman Yeilding, Ming-Chun Hsu, Alexa B. Kimball, and Yin You
- Subjects
Male ,medicine.medical_specialty ,Population ,Hyperlipidemias ,Dermatology ,Diabetes Complications ,Risk Factors ,Internal medicine ,Psoriasis ,Diabetes mellitus ,Hyperlipidemia ,Ustekinumab ,medicine ,Humans ,education ,National Cholesterol Education Program ,Metabolic Syndrome ,education.field_of_study ,Framingham Risk Score ,business.industry ,Middle Aged ,medicine.disease ,Blood pressure ,Cardiovascular Diseases ,Hypertension ,Physical therapy ,Female ,business ,medicine.drug - Abstract
Background Patients with psoriasis are known to have an increased number of cardiovascular (CV) risk factors and be at increased risk for CV events. Objectives We sought to describe and characterize the underdiagnosis and undertreatment of CV risk factors in patients with moderate to severe psoriasis. Methods Medical histories including diabetes, hypertension, and hyperlipidemia were obtained from 2899 patients in 3 phase III ustekinumab trials, a therapeutic anti-interleukin (IL)-12/IL-23p40 monoclonal antibody. Reported history was compared with measured fasting glucose, fasting lipids, and blood pressure. Ten-year Framingham risk scores and the proportion of patients achieving glycemic, lipid, and blood pressure targets were evaluated. Results Significant risk factors existed in patients with moderate to severe psoriasis (58.6% and 28.8% of patients had ≥2 and ≥3 established CV risk factors, respectively). Based on Framingham risk score, 18.6% of patients were at high risk and 12.3% were at intermediate risk for CV events. At baseline, a small proportion of patients with diabetes (2.3%), hypertension (9.1%), or hyperlipidemia (4.9%) were previously without a diagnosis. However, 19.1%, 21.8%, and 38.6% of patients with diabetes, hypertension, or hyperlipidemia, respectively, were untreated at baseline, and the proportion at treatment goal was not ideal (hypertension 59.6% and hyperlipidemia 69.7%), especially for diabetes (36.7%). Limitations Results are based on a clinical trial population and findings may not be generalizable to the general psoriasis population. Conclusions In this moderate to severe psoriasis population, a high prevalence of undiagnosed and undertreated CV risk factors existed, emphasizing the importance of screening patients with psoriasis for CV risk factors.
- Published
- 2012
31. Evidence for Inhibitory Effects of Flupirtine, a Centrally Acting Analgesic, on Delayed Rectifier K+Currents in Motor Neuron-Like Cells
- Author
-
Ming Chun Hsu, Yu Kai Liao, Yuh-Jyh Jong, Sheng Nan Wu, Fang Tzu Wu, and Yi Ching Lo
- Subjects
Article Subject ,business.industry ,Analgesic ,virus diseases ,lcsh:Other systems of medicine ,Pharmacology ,Motor neuron ,lcsh:RZ201-999 ,Inhibitory postsynaptic potential ,K currents ,respiratory tract diseases ,chemistry.chemical_compound ,Delayed rectifier ,medicine.anatomical_structure ,Complementary and alternative medicine ,chemistry ,medicine ,Flupirtine ,business ,Derivative (chemistry) ,Research Article ,medicine.drug - Abstract
Flupirtine (Flu), a triaminopyridine derivative, is a centrally acting, non-opiate analgesic agent. In this study, effects of Flu onK+currents were explored in two types of motor neuron-like cells. Cell exposure to Flu decreased the amplitude of delayed rectifierK+current (IK(DR)) with a concomitant raise in current inactivation in NSC-34 neuronal cells. The dissociation constant for Flu-mediated increase ofIK(DR)inactivation rate was about 9.8 μM. Neither linopirdine (10 μM), NMDA (30 μM), nor gabazine (10 μM) reversed Flu-induced changes inIK(DR)inactivation. Addition of Flu shifted the inactivation curve ofIK(DR)to a hyperpolarized potential. Cumulative inactivation forIK(DR)was elevated in the presence of this compound. Flu increased the amplitude of M-typeK+current (IK(M)) and produced a leftward shift in the activation curve ofIK(M). In another neuronal cells (NG108-15), Flu reducedIK(DR)amplitude and enhanced the inactivation rate ofIK(DR). The results suggest that Flu acts as an open-channel blocker of delayed-rectifierK+channels in motor neurons. Flu-induced block ofIK(DR)is unlinked to binding to NMDA or GABA receptors and the effects of this agent onK+channels are not limited to its action on M-typeK+channels.
- Published
- 2012
32. Bidirectionality of the dentato-rubro-thalamo-cortical tract allows concurrent hypoperfusion in ipsilateral cerebellum and contralateral cerebral hemisphere
- Author
-
Chun-Sheng Hsu, Ming-Chun Hsu, Hsin-Chen He, Shin-Tsu Chang, and Yuan Yang Cheng
- Subjects
Adult ,Perfusion scanning ,Midbrain ,03 medical and health sciences ,0302 clinical medicine ,Atrophy ,Mesencephalon ,Cerebellum ,dentato-rubro-thalamo-cortical tract ,midbrain hemiatrophy syndrome ,Hemiatrophy ,medicine ,Humans ,case report ,Outpatient clinic ,Muscle Strength ,Clinical Case Report ,Postural Balance ,Brain Diseases ,medicine.diagnostic_test ,single-photon emission computed tomography ,business.industry ,Magnetic resonance imaging ,General Medicine ,Anatomy ,medicine.disease ,Magnetic Resonance Imaging ,Superior cerebellar peduncle ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cerebral hemisphere ,Female ,business ,030217 neurology & neurosurgery ,Research Article - Abstract
Rationale The brain circulation of the dentato-rubro-thalamo-cortical tract (DRTT) has been reported for decade, but is rarely observed using nuclear medicine imaging tools, to analyze a patient with midbrain hemiatrophy syndrome. We present a case that revealed notable interruption in the middle of the DRTT. Finding out whether the superior cerebellar peduncle of the midbrain was injured was a decisive element for developing bidirectional effect of DRTT. Patient concerns A 34-year-old right-handed female presented with progressive weakness and bradykinesia in the left-sided limbs for about 6 months. She had difficulty with hand dexterity for activities of daily life and general tasks. She reported poor balance during walking and sitting. Muscle strength was 3 in the left hand and 4 in the foot due to atrophy of left limbs. The circumference of 10 cm proximally/distally from the lateral epicondyle of the humerus was 25.7/23.8 cm at right and 24.2/20.8 cm at left in the upper limbs, and 15 cm proximally/distally from the lateral joint space was 42.1/35.0 cm at right and 43/30.8 cm at left in the lower limbs. The brain magnetic resonance imaging study revealed a small-sized right midbrain. Diagnosis Based on the distinct features of limbs atrophy and the locations of the lesions on the magnetic resonance (MR) imaging, the patient was diagnosed with midbrain hemiatrophy syndrome. Interventions The patient was only willing to accept physical and occupational training programs at our outpatient clinic. Outcomes We utilized serial anatomic and functional neuroimaging of the brain to survey the neurologic deficit. Brain perfusion single-photon emission computed tomography (SPECT) showed hypoperfusion over the left fronto-parietal regions, left anterior temporal region, and left occipital region, and also the left striatum and right cerebellum. Symptoms were gradually recovered with rehabilitation, and he was transferred to a rehabilitation facility on hospital day 40. Lessons This is the first report to demonstrate concurrent hypoperfusion of ipsilateral cerebellum and contralateral cerebral hemisphere observed on SPECT images in a case of midbrain hemiatrophy syndrome. In our case, with midbrain hemiatrophy syndrome could be explained as mutual direction effect of DRTT.
- Published
- 2018
33. Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis
- Author
-
Ming-Chun Hsu, Kristian Reich, Richard G. Langley, Ulrich Mrowietz, Y. Wang, Kaweh Shakery, and Philippe Szapary
- Subjects
medicine.medical_specialty ,business.industry ,General Arts and Humanities ,Moderate to severe psoriasis ,Ustekinumab ,medicine ,In patient ,business ,Dermatology ,medicine.drug - Abstract
Background Ustekinumab has demonstrated significant efficacy and favorable safety in patients with moderate to severe psoriasis. Objective Characterization of patients achieving marked clinical responses (Psoriasis Area and Severity Index [PASI] 90 or Physician's Global Assessment [PGA] of cleared) in two double-blind, placebo-controlled, phase III studies. Methods PHOENIX 1 (n=766) and PHOENIX 2 (n=1,230) patients were randomized to receive placebo or ustekinumab 45 or 90 mg at weeks 0 and 4, then every 12 weeks. At week 12, placebo patients crossed over to ustekinumab. Marked responses, defined as PASI 90 or PGA of cleared, are reported. Results A significantly higher proportion of ustekinumab-treated patients in PHOENIX 1 (39.9%) and PHOENIX 2 (47.0%) achieved marked responses at week 12, compared with placebo-treated patients (pConclusion Significant proportions of ustekinumab-treated patients with moderate to severe psoriasis achieved marked clinical responses through week 28. Ustekinumab had a favorable risk-benefit profile through up to 18 months of follow-up.
- Published
- 2010
34. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- Author
-
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T Dooley, and Kristian Reich
- Subjects
General Medicine - Published
- 2008
35. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
- Author
-
Stephen Xu, Shu Li, Kristian Reich, Christopher E.M. Griffiths, Cynthia Guzzo, Richard K. Scher, Frank O. Nestle, Phoebe Rich, and Ming Chun Hsu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Dermatology ,Placebo ,Nail Diseases ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Psoriasis Area and Severity Index ,Psoriasis ,medicine ,Humans ,skin and connective tissue diseases ,030203 arthritis & rheumatology ,integumentary system ,business.industry ,Onycholysis ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Infliximab ,3. Good health ,medicine.anatomical_structure ,Nail disease ,Nail (anatomy) ,Female ,business ,medicine.drug - Abstract
Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited.Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated.This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24.Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P.001).The study did not evaluate nail response beyond 1 year.Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement.
- Published
- 2008
36. Heat dissipation improvement design for QSFP connector
- Author
-
Hung-Wen Lin and Ming-Chun Hsu
- Subjects
Engineering ,business.industry ,QSFP ,Design flow ,Integrated circuit ,Heat sink ,Fixture ,Electromagnetic interference ,law.invention ,Taguchi methods ,law ,Electronic engineering ,Object-relational impedance mismatch ,business - Abstract
QSFP connector is used for high bandwidth telecommunication and data communication applications. It has strict limitations on the thermal dissipation, the impedance mismatch and the electromagnetic interference. This paper proposes to modify the plastic fixture wafers and to insert additional internal heat sinker, thereby creating an new air flow channel in QSFP connector to enhance the thermal dissipation. Both the software simulation and the hardware measurement are applied to verify the performance of the proposed design. This paper also proposes an improved size design flow for the top-layer heat sinker by using Taguchi method. The designed signal factors, the control levels setup, the mathematical analysis on the simulation results are described to demonstrate the design flow.
- Published
- 2015
37. Piceatannol upregulates endothelial heme oxygenase-1 expression via novel protein kinase C and tyrosine kinase pathways
- Author
-
Ming-Chun Hsu, Being-Sun Wung, C.C. Wu, and Chia-Wen Hsieh
- Subjects
Cell Survival ,Blotting, Western ,Gene Expression Regulation, Enzymologic ,chemistry.chemical_compound ,Superoxides ,Stilbenes ,Animals ,Buthionine sulfoximine ,RNA, Messenger ,Cells, Cultured ,Protein Kinase C ,Protein kinase C ,Pharmacology ,Piceatannol ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,Tumor Necrosis Factor-alpha ,Kinase ,Protein-Tyrosine Kinases ,Intercellular Adhesion Molecule-1 ,Molecular biology ,Up-Regulation ,Heme oxygenase ,Calphostin C ,chemistry ,Enzyme Induction ,Mitogen-activated protein kinase ,Luminescent Measurements ,biology.protein ,Cattle ,Endothelium, Vascular ,Tyrosine kinase ,Heme Oxygenase-1 - Abstract
Piceatannol is an anti-inflammatory and anti-proliferative plant-derived stilbene. Heme oxygenase-1 (HO-1) is a cytoprotective enzyme to activate by various phytochemicals. In this study, we examined the ability of piceatannol to upregulate HO-1 expression in endothelial cells. We found piceatannol at micromolar (10-50 microM) concentrations dramatically increased HO-1 protein levels in a time-dependent manner. Piceatannol was similarly potent in the induction of HO-1 as hemin, arsenate, and 15d-PGJ2, and was more potent than some other phytochemicals including curcumin, EGCG, baicalein, and quercetin. In contrast, the similar chemical structure compounds, trans-stilbene, stilbene oxide, and resveratrol had no HO-1-inducing effects, suggesting a critical role for the hydroxyl groups in HO-1 induction. No cytotoxicity and superoxide production was observed after 10-50 microM piceatannol treatments. Piceatannol-mediated HO-1 induction was abrogated in the presence of N-acetylcysteine and glutathione, but not by other antioxidants. Induction of HO-1 by piceatannol was further enhanced by using buthionine sulfoximine. In addition, we determined that tyrosine kinase was involved in the induction of HO-1 by using tyrosine kinase inhibitors, herbimycin A, erbstatin, and genistein; in contrast, no significant changes in the pretreatment of PI3 kinase or MAP kinase inhibitors was determined. HO-1 induction was blocked by the protein kinase C inhibitors calphostin C, rottlerin, and long PMA pretreatment, whereas conventional PKC inhibitors, Go6976, and Ca2+ chelator BAPTA/AM, had no effect. Elevated HO-1 protein levels were associated with the inhibition of tumor necrosis factor-alpha (TNFalpha)-induced intercellular adhesion molecule-1 (ICAM-1) expression. Treating ECs with zinc protoporphyrin, an HO-1 inhibito blocked the anti-inflammatory effect of piceatannol. In summary, this study identified piceatannol as a novel phytochemical inducer of HO-1 expression and identified the mechanisms involved in this process.
- Published
- 2006
38. Enhancement of the convective heat transfer for a reciprocating impinging jet flow
- Author
-
Chia-Ta Hsieh, Yuan-Tang Lin, and Ming-Chun Hsu
- Subjects
Physics ,Jet (fluid) ,Convective heat transfer ,Physics::Instrumentation and Detectors ,Astrophysics::High Energy Astrophysical Phenomena ,General Chemical Engineering ,Thermodynamics ,Mechanics ,Condensed Matter Physics ,Atomic and Molecular Physics, and Optics ,Isothermal process ,Physics::Fluid Dynamics ,Reciprocating motion ,Jet flow - Abstract
The convective heat transferred from the isothermal plate impinged by the jet flow with different reciprocating frequencies are studied computationally. A reciprocating jet impinges on the plate surface is available velocity to remove the heat from the plate surface, it implies that the reciprocating impinging jet is one of the good methods to enhance heat transferred from the plate surface
- Published
- 2003
39. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- Author
-
Daphne Chan, Ming-Chun Hsu, Neil J. Korman, Richard G. Langley, Mark Lebwohl, Yves Poulin, Y. Wasfi, Jörg C. Prinz, Yin You, Philippe Szapary, Gerald G. Krueger, and Kristian Reich
- Subjects
Male ,medicine.medical_specialty ,Population ,Dermatology ,Placebo ,Drug Administration Schedule ,law.invention ,Randomized controlled trial ,Double-Blind Method ,Psoriasis Area and Severity Index ,law ,Internal medicine ,Ustekinumab ,Medicine ,Humans ,Psoriasis ,Dosing ,education ,education.field_of_study ,Cross-Over Studies ,Dose-Response Relationship, Drug ,business.industry ,Body Weight ,Middle Aged ,Crossover study ,Surgery ,Clinical trial ,Treatment Outcome ,Female ,Dermatologic Agents ,business ,medicine.drug ,Follow-Up Studies - Abstract
Summary Background Evaluation of the dosing flexibility and long-term efficacy of biological agents is limited. Objectives To evaluate the long-term efficacy and safety of ustekinumab with and without dosing adjustment in the 5-year PHOENIX 2 study. Methods Patients were randomized to placebo or ustekinumab (45 or 90 mg) at weeks 0, 4, then every 12 weeks; patients receiving placebo crossed-over at week 12. Dosing adjustments were permitted at/beyond week 28 for early adjusters (weeks 28 or 40 per response); late adjusters (during long-term extension per investigator judgement); and nonadjusters (maintained randomized treatment throughout the study). Efficacy and safety were evaluated through weeks 244 and 264, respectively. Results In the overall population, 70% (849 of 1212) of ustekinumab-treated patients completed treatment through week 244, with high proportions of patients responding to the 45-mg and 90-mg doses, respectively: 75% improvement in Psoriasis Area and Severity Index (PASI 75) (76·5% and 78·6%) and PASI 90 (50·0% and 55·5%). Approximately 20% of patients were early adjusters, 30% were late adjusters and 50% were nonadjusters. Approximately half of the late adjusters initiated adjustments after already achieving PASI 75. Improved response was generally observed following dosing adjustments. Through week 264, safety event rates did not increase and event rates were generally comparable between dose groups and between patients with and without dosing adjustment. Conclusions Treatment with ustekinumab for up to 5 years was safe and effective. Improved response was generally demonstrated following dosing adjustments; further investigations are required to quantify actual incremental benefits. The results also suggest that some patients may desire treatment goals beyond PASI 75.
- Published
- 2014
40. Substituting sedentary time with physical activity in youngest-old to oldest-old community-dwelling older adults: Associations with body composition
- Author
-
Ting-Fu Lai, Yung Liao, Ming-Chun Hsueh, Hsin-Yen Yen, Jong-Hwan Park, and Jae Hyeok Chang
- Subjects
adiposity ,elderly ,accelerometry ,body composition ,inactivity ,Public aspects of medicine ,RA1-1270 - Abstract
IntroductionSeveral studies have suggested that physical activity and sedentary behavior are strongly and independently associated with body composition and obesity. However, few studies have investigated whether substituting sedentary time with moderate-to-vigorous physical activity is associated with body composition in older adults, especially among those older than 75 years.MethodsThis study examined the associations between replacing sedentary time with physical activity and obesity indices in a sample of 199 community-dwelling older Taiwanese adults (52.3% women; 80.6 ± 7.0 years). Physical activity and sedentary behavior were measured using the triaxial accelerometer (GT3X+, ActiGraph). Body composition indices were computed through a bioelectrical impedance analysis of body fat percentage and appendicular skeletal muscle mass index. Waist circumference and body mass index were measured by trained personnel. Isotemporal substitution analyses estimated these associations after adjusting for sociodemographic characteristics and nutritional status.ResultsThe study showed that substituting 30 min of sedentary behavior per day with moderate-to-vigorous physical activity was associated with lower body fat percentage (B = −1.408, 95% CI = −2.55, −0.264), body mass index (B = −0.681, 95% CI = −1.300, −0.061), and waist circumference (B = −2.301, 95% CI = −4.062, −0.539) after adjusting for covariates. Substituting 30 min of light physical activity per day with moderate-to-vigorous physical activity was associated with lower waist circumference (B = −2.230, 95% CI = −4.173, −0.287) after adjusting for covariates. Stratified analyses indicated that associations were stronger in youngest-old older adults, and in older adults with a normal nutritional status (vs. underweight status).DiscussionThese findings confirm the importance of reducing sedentary behavior and increasing moderate-to-vigorous physical activity among older adults to improve their physical health, as well as highlighting the importance of taking into account nutritional status and age group.
- Published
- 2022
- Full Text
- View/download PDF
41. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use
- Author
-
Carrie, Brodmerkel, Eric, Wadman, Richard G, Langley, Kim A A, Papp, Marc, Bourcier, Yves, Poulin, Vincent, Ho, Lyn, Guenther, Rod, Kunynetz, Simon, Nigen, Ronald, Vender, Norman, Wasel, Ming-Chun, Hsu, and Philippe, Szapary
- Subjects
Adult ,Male ,Pneumococcal Vaccines ,Streptococcus pneumoniae ,Vaccination ,Tetanus Toxoid ,Humans ,Psoriasis ,Female ,Ustekinumab ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Antibodies - Abstract
Little is known about the impact of long-term use of immunosuppressive agents on immune response.Assess the impact of continuous maintenance ustekinumab treatment on patients' ability to mount immune responses to pneumococcal (T-cell-independent) and tetanus toxoid (T-cell-dependent) vaccines.Ustekinumab-treated patients with moderate-to-severe psoriasis treated in the long-term extension of the Phase 3 PHOENIX 2 trial (n=60) were compared with control psoriasis patients not receiving systemic therapy (n=56). Patients were vaccinated with both 23-valent pneumococcal and tetanus toxoid vaccines. Serum samples collected pre-vaccination and 4 weeks post-vaccination were assessed for antibody responses.No differences in the ability of ustekinumab-treated patients to respond to pneumococcal or tetanus toxoid vaccinations were observed compared with controls. A ≥2-fold increase in antibody levels in ≥7 of 14 serotypes of the pneumococcal vaccine was observed in ustekinumab-treated (96.6%) and untreated control (92.6%) patients following vaccination. Ustekinumab-treated patients achieved a ≥4-fold increase (84.7%) in anti-tetanus antibody vs. 77.8% in the control group. No differences were detected in ex-vivo responses to anti-CD3/CD28 or tetanus toxoid between ustekinumab-treated and control groups.Long-term treatment (≥3 years) with ustekinumab does not compromise the immune response to T-cell-dependent/-independent vaccines in patients with moderate-to-severe psoriasis.
- Published
- 2013
42. Bidirectionality of the dentato-rubro-thalamo-cortical tract allows concurrent hypoperfusion in ipsilateral cerebellum and contralateral cerebral hemisphere: A case report.
- Author
-
Hsin-Chen He, Ming-Chun Hsu, Chun-Sheng Hsu, Yuan-Yang Cheng, Shin-Tsu Chang, He, Hsin-Chen, Hsu, Ming-Chun, Hsu, Chun-Sheng, Cheng, Yuan-Yang, and Chang, Shin-Tsu
- Published
- 2018
- Full Text
- View/download PDF
43. Is achieving 7,000 steps/day cross-sectionally and prospectively associated with older adults’ lower-extremity performance?
- Author
-
Ming-Chun Hsueh, Chien-Yu Lin, Ting-Fu Lai, Yi-Chien Yu, Shao-Hsi Chang, Ju Yong Bae, and Yung Liao
- Subjects
Accelerometer ,Physical activity ,Walking ,Physical function ,Older adults ,Taiwan ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Evidence regarding the association between daily steps recommendation and older adults’ lower limb strength is lacking; thus, this study investigated whether taking at least 7,000 steps/day is cross-sectionally and prospectively related to lower-extremity performance in older Taiwanese adults. Methods There were 89 community-dwelling adults aged over 60 years (mean age: 69.5 years) attending both baseline and follow-up surveys. This study used adjusted logistic regression analysis to explore cross-sectional and prospective relationships between their accelerometer-assessed daily steps and lower-extremity performance (five-times-sit-to-stand test). Results This study found the older adults who took 7,000 steps/day were more likely to have better lower-extremity performance cross-sectionally (odds ratio [OR] = 3.82; 95 % confidence interval [CI]: 1.04, 13.95; p = 0.04), as well as to maintain or increase their lower-extremity performance prospectively (OR = 3.53; 95 % CI: 1.05, 11.84; p = 0.04). Conclusions Our findings support a minimum recommended level of step-based physical activity for older adults, namely, 7,000 steps/day, as beneficial for maintaining or increasing older adults’ lower-extremity performance.
- Published
- 2021
- Full Text
- View/download PDF
44. Is functional fitness performance a useful predictor of risk of falls among community-dwelling older adults?
- Author
-
Hsin-Hung Ho, I-Yao Fang, Yi-Chien Yu, Yi-Ping Huang, I-Ling Kuo, Li-Ting Wang, Ming-Chueh Tsai, Shao-Hsi Chang, and Ming-Chun Hsueh
- Subjects
Elderly ,Physical performance ,Physical function ,Frailty ,Taiwan ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Falls among older adults are a serious public health problem. Many studies indicate that positive functional fitness performance decreases the risk of falls. A limited amount of previous study has investigated the association between broad functional fitness and the fall risk. This study examines the associations between functional fitness and the risk of falling among community-dwelling older adults. Methods Three waves of cross-sectional data were collected from 2017 to 2019 in Taipei City, Taiwan. Six hundred sixty-five participants aged ≥65 years were randomly recruited from 12 districts of Taipei. Eight functional fitness tests (i.e., back scratch, chair-sit and-reach, 8-ft up-and-go, 30-s sit-to-stand, 30-s arm curl, 30-s single-leg stance, 2-min step, and hand grip strength tests) were performed to record the physical performance of older subjects. A Chinese version of the fall-risk questionnaire (FRQ) was used to calculate the fall risk scores. Linear regression and logistic regression were utilized to estimate the relationships of each functional fitness and fall risk. Result The results showed that 37.45% of older adults had a high risk of falling. It was found for each functional fitness that performance was linearly associated with the risk of falling. Moreover, older adults with low-performance levels in all functional fitness except back-scratching were more likely to have a higher risk of falling. Conclusions Our study indicated that functional fitness performance appears to provide valid predictive guidance for reducing the risk of falling among the older population.
- Published
- 2021
- Full Text
- View/download PDF
45. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up
- Author
-
Kristian, Reich, Kim A, Papp, Christopher E M, Griffiths, Philippe O, Szapary, Newman, Yeilding, Yasmine, Wasfi, Elyssa, Ott, Ming-Chun, Hsu, Mark, Lebwohl, and Kenneth B, Gordon
- Subjects
Adult ,Male ,Cross-Over Studies ,Time Factors ,Dose-Response Relationship, Drug ,Antibodies, Monoclonal ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Double-Blind Method ,Humans ,Psoriasis ,Female ,Ustekinumab ,Dermatologic Agents ,Follow-Up Studies - Abstract
The efficacy and safety profile of ustekinumab with up to three years of exposure suggested a favorable benefit-risk profile in patients with moderate to severe psoriasis.To evaluate the safety of ustekinumab in patients with moderate to severe psoriasis treated for up to four years.Safety data were pooled across four Phase II/III randomized controlled trials. Rates over time and cumulative rates of adverse events (AEs), AEs leading to treatment discontinuation, serious adverse events (SAEs), serious infections, malignancies, and major adverse cardiovascular events (MACE) (i.e., cardiovascular death, myocardial infarction [MI], or stroke as adjudicated by an independent panel of academic cardiologists) were evaluated. Observed rates of AEs of interest were compared with those expected in the general (malignancies, MI, and stroke) and psoriasis (serious infections, MI, and stroke) populations.Overall, 3,117 patients were followed for up to four years (6,791 patient-years). Rates of AEs, AEs leading to treatment discontinuation, and SAEs remained stable over time, whereas cumulative rates were generally comparable between patients who received 45 mg and 90 mg of ustekinumab. The rates of AEs of interest also remained stable over time, and cumulative rates per 100 patient-years were 0.80 and 1.32 (serious infections), 0.70 and 0.53 (nonmelanoma skin cancer), 0.63 and 0.61 (other malignancies), and 0.56 and 0.46 (MACE) in patients treated with 45 mg and 90 mg, respectively. Rates of AEs of interest were consistent with those in the general and psoriasis populations.The safety profile of long-term ustekinumab treatment with up to four years of continuous use remains consistent with previous reports, with no evidence of cumulative toxicity.
- Published
- 2012
46. Chip Design of an UWB, High Gain and Low Noise Amplifier for Wireless Applications
- Author
-
Ron-Yi Liu, Jiun-Yu Wen, Jhin-Fang Huang, and Ming-Chun Hsu
- Subjects
Physics ,CMOS ,Noise measurement ,business.industry ,Frequency band ,Amplifier ,Electrical engineering ,Ultra-wideband ,business ,Telecommunications ,Noise figure ,Chip ,Low-noise amplifier - Abstract
An ultra-wideband (UWB), high gain and low-noise amplifier (LNA) for wireless applications is presented in this paper. Operating at the frequency band of 0.8-6.0 GHz and fabricated in TSMC 0.18-um technology, the measured results show the gain of 17-19 dB, the noise figure (NF) less than 4.8 dB, the input third-order intercept point (IIP3) of -17 dBm, the reverse isolation less than -25 dB and the power dissipation of 43.2 mW at 1.8 V voltage supply. The chip area including pads is only 1.027mm2.
- Published
- 2011
47. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
- Author
-
Philippe Szapary, Christopher E.M. Griffiths, Newman Yeilding, Shu Li, Mark Lebwohl, Cynthia Guzzo, Jörg C. Prinz, Bruce Strober, Craig L. Leonardi, and Ming Chun Hsu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Safety Management ,Time Factors ,Drug-Related Side Effects and Adverse Reactions ,Dermatology ,Placebo ,Antibodies, Monoclonal, Humanized ,Risk Assessment ,Severity of Illness Index ,Drug Administration Schedule ,Receptors, Tumor Necrosis Factor ,law.invention ,Etanercept ,Randomized controlled trial ,Double-Blind Method ,law ,Psoriasis Area and Severity Index ,Psoriasis ,Internal medicine ,Ustekinumab ,medicine ,Humans ,Adverse effect ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Surgery ,Discontinuation ,Clinical trial ,Treatment Outcome ,Evaluation Studies as Topic ,Immunoglobulin G ,Female ,business ,medicine.drug ,Follow-Up Studies - Abstract
Background Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of moderate-to-severe psoriasis. Objective To evaluate overall pooled study data to assess the safety profile of ustekinumab through 3 years of treatment. Methods Cumulative safety data were pooled from studies in 3117 ustekinumab-treated patients. Results During the placebo-controlled periods (Phase 2, PHOENIX 1, PHOENIX 2), rates of adverse events (AEs) were comparable among patients treated with placebo (50.4%), with ustekinumab 45 mg (57.6%), or with ustekinumab 90 mg (51.6%); similar findings were observed during the controlled period of the ACCEPT trial (etanercept: 70.0%; ustekinumab 45 mg: 66.0%; and ustekinumab 90 mg: 69.2%). Rates of serious AEs (SAEs) through the controlled periods were low and comparable among all groups (1.2% to 1.9%). Through 3 years, rates of AEs per 100 patient-years of follow-up (/100 patient-yrs) (45 mg: 305.2/100 patient-yrs; 90 mg: 305.9/100 patient-yrs) and SAEs (45 mg: 6.8/100 patient-yrs; 90 mg: 8.2/100 patient-yrs) were comparable between ustekinumab doses. No cases of demyelination or tuberculosis were reported in these trials. No dose response in rates of AEs, overall infections, or SAEs was apparent through 3 years. Rates of AEs, infections, SAEs, and AEs leading to study agent discontinuation remained generally stable or decreased over time. Limitations Controlled periods did not extend beyond 12 to 20 weeks. Only 1247 of the 3117 ustekinumab-treated patients were treated for 2 or more years. Conclusions The safety profile of continued ustekinumab exposure through up to 3 years is favorable and consistent with previous short-term reports.
- Published
- 2011
48. Marginally restricted linear-optimal designs
- Author
-
Mong-Na Lo Huang and Ming-Chun Hsu
- Subjects
Statistics and Probability ,Optimal design ,Mathematical optimization ,Iterative method ,Applied Mathematics ,General function ,Extrapolation ,Fréchet derivative ,Regression analysis ,Statistics, Probability and Uncertainty ,Marginal distribution ,Equivalence (formal languages) ,Mathematics - Abstract
In this work, we consider the problem of constructing linear-optimal designs for regression models, when some of the factors are not under the control of the experimenters. Such designs are referred to as marginally restricted (MR for brevity) linear-optimal designs. At first we make use of Frechet derivative to the general function o to characterize MR o-optimal designs. Then we apply this result to prove an equivalence theorem for MR linear-optimal designs. Particularly, we discuss applications to design problems in extrapolation at a point and A-optimality, which are special cases for linear criteria. An iterative algorithm for generating MR linear-optimal designs is also presented.
- Published
- 1993
49. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials
- Author
-
Shu Li, Kristian Reich, Steven Fakharzadeh, Kenneth B. Gordon, Ming Chun Hsu, Newman Yeilding, Richard G. Langley, Alexa B. Kimball, Kim A. Papp, Philippe Szapary, Vincent T. Ho, and Cynthia Guzzo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Safety Management ,Time Factors ,Drug-Related Side Effects and Adverse Reactions ,Population ,Dermatology ,Placebo ,Antibodies, Monoclonal, Humanized ,Infections ,Risk Assessment ,Severity of Illness Index ,Drug Administration Schedule ,law.invention ,Randomized controlled trial ,Double-Blind Method ,Interquartile range ,law ,Psoriasis ,Internal medicine ,Neoplasms ,Ustekinumab ,Surveillance, Epidemiology, and End Results ,Medicine ,Humans ,education ,education.field_of_study ,Dose-Response Relationship, Drug ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Long-Term Care ,Clinical trial ,Treatment Outcome ,Female ,business ,medicine.drug ,Follow-Up Studies - Abstract
Background Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of moderate to severe psoriasis. Objective We sought to evaluate the impact of ustekinumab on infections and malignancies, both theoretical risks of blocking IL-12 and IL-23, in patients exposed up to 3 years. Methods Rates of infections and malignancies were evaluated in cumulative safety data from 3117 ustekinumab-treated patients across 4 studies. Results During the placebo-controlled periods, rates of overall infections per 100 patient-years were similar among placebo (121.0), ustekinumab 45-mg (145.7), and ustekinumab 90-mg (132.2) groups, with overlapping confidence intervals, and remained stable through 3 years in ustekinumab groups. Rates of serious infections during the placebo-controlled periods were similar between placebo (1.70) and 90-mg (1.97) groups, yet lower in the 45-mg group (0.49). Rates remained stable (90 mg) or decreased (45 mg) over time, and were comparable with those for the US psoriasis population based on a managed care database. Rates of malignancies during the placebo-controlled periods were comparable among groups (placebo: 1.70; 45 mg: 0.99; 90 mg: 0.98) and remained stable over time in ustekinumab groups. Rates of malignancies, excluding nonmelanoma skin cancer, were comparable with rates expected in the general US population based on the Surveillance, Epidemiology, and End Results database. Limitations Controlled periods do not extend beyond 12 to 20 weeks. Only 1247 patients were treated for at least 2 years, to date. Comparator database populations may not fully represent the clinical trial population. Conclusions The emerging safety profile of ustekinumab remains favorable and does not suggest increased rates of infection or malignancy through 3 years.
- Published
- 2010
50. Develop a HMM-based Taiwanese text-to-speech system
- Author
-
Yu-Hsien Chiu, Yung Ji Sher, Kao-Chi Chung, and Ming-Chun Hsu
- Subjects
Text corpus ,business.industry ,Computer science ,Speech recognition ,Speech technology ,Speech synthesis ,computer.software_genre ,Speech processing ,Mandarin Chinese ,Spelling ,language.human_language ,Formant ,language ,Artificial intelligence ,business ,Hidden Markov model ,computer ,Natural language processing - Abstract
In Taiwan, speech technology development has been focused on Mandarin system; there is lack of related researches of domestic Taiwanese speech. This study is aimed to develop a HMM-based Taiwanese speech synthesis system, and the established sub-syllables units' database is used to be the synthesis units for all of the possible Taiwanese semantic syllables. The multiple accent corpus-based databases were developed by all combination of basic phonemes of vowels, consonants and 8-tones in Modern Literal Taiwanese (MLT) in this study. Based on the phoneme tables, this research provide fundamental database for speech analysis and synthesis in Taiwanese spelling systems. The principles and procedures in constructing phonetically balanced sentences are constituted by Taiwanese grammatical in syntax and semantics, and employ all the possible Taiwanese. Pattern recognition was applied to extract features' parameter codes including formants, pitch, amplitudes, and duration. The collected text corpus consists of MLT sentences and syllables from MLT books. A Taiwanese balanced sentences speech database including MLT sentences is established through training and analyzing system developed by windows programming, and another rare phoneme units are generated to be included in the database. The phonetic set of Taiwanese tonal phonemes is generated from the HTK recognition results. Through this research, the established TTS system may contribute to the education and training of native Taiwanese for the children, elder, and speech disabled.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.